Key result
Targeted drug therapy mitigates cardiovascular risks from diabetic autonomic neuropathy affecting up to ~75% of patients.
Why the study?
Diabetic autonomic neuropathy occurs frequently in diabetic patients and is associated with serious cardiac and systemic complications, requiring improved understanding of its features and treatment.
Diabetic autonomic neuropathy significantly increases the risk of adverse cardiovascular events, but appropriate drug therapy can help mitigate these risks and improve autonomic function.
Alerts clinicians to racial disparities in neuropathy burden; leaves open optimal therapies to reduce associated cardiovascular risks.
Diabetic autonomic neuropathy (DAN) occurs in approximately half of Caucasian patients with diabetes and perhaps three-fourths of black diabetic patients. This may be asymptomatic for several years, but the majority of patients with DAN eventually exhibit symptoms of diarrhea, cardiac arrhythmias, sexual dysfunction, and abnormal sweating. Prolonged hyperglycemia results in damage to the autonomic nervous system (ANS), particularly the vagus nerve and other parts of the parasympathetic division. DAN is associated with increased risk of sudden death, high-risk cardiac arrhythmias, myocardial infarction, and death from other causes. Objective testing of autonomic nervous system function yields specific information that affects treatment decisions. Drug therapy can effect improvements in ANS function and reduce these risks. Complications of diabetes that result from ANS dysfunction can be partly reversed or their progress can be slowed by appropriate drug therapy. Features, implications, and therapy of the most common complications resulting from DAN are reviewed, and suggestions for pharmacist involvement in the care of these difficult patients are offered.
No takes yet. Share an insight, caveat, or question.
Roy C. Parish (1999) conducted a review in Diabetic Autonomic Neuropathy. Diabetic autonomic neuropathy affects approximately 50% of Caucasian and 75% of black patients with diabetes, increasing cardiovascular risks that can be mitigated by appropriate drug therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: